Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial

作者：Zhiqiang Song, Liya Zhou, Liya Zhou, Weihong Wang, Cheng Lan, Tongyu Tang, Jun Xie, Huizhen Fan, Xuehong Wang, Xiuli Zuo, Yin Zhu, Chengxia Liu, Yongsong Gu, Huang Feng, Xiang Gao, Hong Zhang, Hong Zhang, Jing Chen, Guozhu Geng, Zhenkun Ma, Zhiqiang Song, Liya Zhou, Liya Zhou, Jing Chen, Weihong Wang, Cheng Lan, Tongyu Tang, Jun Xie, Huizhen Fan, Xuehong Wang, Xiuli Zuo, Yin Zhu, Chengxia Liu, Yongsong Gu, Huang Feng, Xiang Gao, Qing Zhang, Hong Zhang, Jianguang Xu, Qizhi Wang, Aijun Liao, Xiaojie Zhang, Chuanxin Zou, Xing Li, Min Xu, Xing Li, Qin Du, Jianwei Zheng, Huixin Chen, Shaoqi Yang, Hongzhi Xu, Meihua Xu, Lei Chen, Fangfang Li, Lei Chen, Zhirong Zeng, Tao Chen, Yanbo Zhen, Shiyun Tan, Xin Zeng, Hong Gao, Hong Wang, Pengyuan Zheng, Guozhu Geng, Zhenkun Ma · 发表于：The Lancet Infectious Diseases · 年份：2025 · DOI：10.1016/s1473-3099(25)00438-4 · 被引用次数：9 · 研究领域：Helicobacter pylori-related gastroenterology studies、Microscopic Colitis、Clostridium difficile and Clostridium perfringens research